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ABSTRACT
Background: Dendritic cell (DC) defects may contribute
to chronicity in hepatitis C virus (HCV) infection and
determine response to PEG–interferon and ribavirin
therapy via poor T cell stimulation. Studies to date have
produced inconsistent results regarding DC maturation
and function: no large study has examined DCs before and
after therapy.
Aims: We examined if DC defects in maturation and
chemotaxis are present by comparing therapeutic
responders to non-responders.
Methods: We analysed peripheral DCs of 64 HCV
genotype 1-infected patients from the Virahep-C study
2 weeks before and 24 weeks after therapy. We used
flow cytometry to enumerate plasmacytoid DC (pDC) and
myeloid DCs (mDC) and quantify expression of chemokine
receptors and maturation markers. Chemotaxis was
measured with an in vitro assay.
Results: Pre-treatment frequencies of pDCs and mDCs
were significantly lower in HCV patients than controls and
successful therapy normalised pDCs. Levels of CXCR3 and
CXCR4 on pDCs were higher at baseline compared to
normal controls and decreased with therapy. Pre-therapy
levels of co-stimulatory marker CD40 and the maturation
marker CD83 were higher in pDCs of patients chronically
infected with HCV compared to normal patients, and
levels of both markers dropped significantly with therapy
in the SVR+ group only. Other maturation markers (CD86
and CCR7) were not elevated suggesting a partially
activated phenotype. Baseline chemotaxis of pDCs to
CXCL12 and CXCL10 predicted failure of antiviral response
and correlated with the histological activity index
inflammation score.
Conclusions: Plasmacytoid DC defects exist in chronic
HCV and successful antiviral therapy normalises many
phenotypic and functional abnormalities.
Hepatitis C virus (HCV) has a global prevalence of
3% and up to 70% of individuals exposed to HCV
develop viral persistence.
12HCV causes substantial
worldwide morbidity and mortality. Twenty per
cent of infected patients eventually develop cir-
rhosis and HCV infection is a leading cause of liver
transplantation.
3 Current therapy with interferon
and ribavirin is only effective in about half of
patients and causes significant morbidity.
4 Thus
understanding the mechanism of therapeutic suc-
cess and failure has important clinical relevance for
developing improved therapies and predicting non-
response. Patients who spontaneously clear infec-
tion have strong and broad T cell responses while
patients with chronic HCV have weak and
functionally impaired responses characterised by
poor proliferation, impaired cytotoxicity and
reduced cytokine secretion after antigen expo-
sure.
3 5–7 Higher pre-treatment CD4
+ T cell inter-
feron c responses to HCV proteins are associated
with higher rates of sustained virological response
(SVR).
8
Dendritic cells (DCs) are efficient and potent
antigen presenters and activators of antigen-
specific T cells and adaptive immunity.
9–12
Defective DC activation of T cells may underlie
poor T cell responsiveness in HCV infection, and
may, in part, determine the response to therapy.
13
Human peripheral blood DCs are currently cate-
gorised into two major subsets: myeloid DCs
(mDCs) and plasmacytoid DCs (pDCs). Myeloid
DCs are effective antigen presenters to T cells and
secrete interleukin 12, while pDCs are the most
potent secretors of antiviral type-I interferons like
interferon a.
10 DCs migrate to sites of inflamma-
tion, sample antigens, and integrate generic micro-
bial danger signals via innate immune receptors,
named pathogen recognition receptors (PRRs), that
recognise pathogen-associated molecular patterns
(PAMPs).
13 PRR signals combine with signals from
inflammatory cytokines to activate DCs, causing
up-regulation of co-stimulatory molecules like
CD40 and CD86. DCs then migrate to lymphoid
tissue where they activate antigen-specific CD4
and CD8 T cells by presenting antigens on major
histocompatibility complex (MHC) class I and II
molecules.
11 14
Reports of global immune dysfunction in HCV
infection are controversial; some studies have
suggested that HCV patients have poorer response
to hepatitis B vaccination
15 and higher rates of
infection with herpes simplex virus (HSV).
16
However, strong global immune dysfunction as
seen in HIV/AIDS is not seen. DC dysfunction
may be restricted to the HCV-specific response.
Studies of impaired DC function in chronic HCV
have yielded variable results; most use monocyte-
derived DCs from HCV patients, not DCs analysed
directly ex vivo. Some authors have found faulty
responses to general PRR stimulation including
decreased IFNa and IL12 secretion, reduced CD86
expression, decreased HLA-DR (MHC class II) and
impaired stimulation of T cells in mixed lympho-
cyte reaction compared with normal controls.
13 17–24
Specific HCV proteins like core and E2 can cause
DC dysfunction in tissue culture models.
13 19 Other
authors, including those using direct ex vivo
human samples or a chimpanzee model of HCV
Hepatology
964 Gut 2009;58:964–973. doi:10.1136/gut.2008.168948have found no defects.
13 25–29 It has been consistently shown in
HCV infection that pDC and mDC numbers are reduced in the
peripheral compartment compared with normal controls,
whereas reports have described increased numbers of DCs in
the livers of HCV patients, suggesting hepatic DC sequestra-
tion.
13 18 22 30 31 The unresolved controversies listed above high-
light the need for further study of DCs in HCV infection.
Chemokines and chemokine receptors are important regula-
tors of DC migration to specific anatomic areas such as lymph
nodes and sites of infection, and thus have an important effect
on DC function. Chemokines are elevated in HCV patients,
32
and in vitro studies have suggested that the HCV protein E2 can
inhibit DC chemotaxis.
30 Serum levels of the chemokines IL8
(CXCL8) and IP-10 (CXCL10) are elevated compared with
normal controls and increased levels are associated with higher
HCV viral levels and disease activity while lower levels have
been associated with improved response to combination
therapy.
33–35 Additionally, HCV patients have high levels of
CXCR3, CXCR4, CCR5 and CCR7 expression on liver-
infiltrating lymphocytes, and the corresponding chemokines
for these receptors are also increased in the liver and the
plasma.
32 36 To date, no large study has examined levels of these
receptors on DC subsets or chemotaxis of DC before and after
therapy for HCV directly ex vivo.
We hypothesised that baseline differences in DC maturation
and function may determine an individual’s response to PEG–
IFN/ribavirin therapy. We also postulated that patients who
ultimately have a sustained virological response (SVR) might
Table 1 Demographic and clinical features of 64 patients from the Virahep-C study
n=64
Sustained virological response
Non-responders Responders
(n=34) (n=30)
Age (years)
Mean (SD) 48.1 (8.4) 48.1 (9.4) 48.1 (7.3)
Median (25th, 75th) 48 (44.0, 53.0) 48 (45.0, 54.0) 48 (43.0, 50.0)
Race
African–American 34 (53.1%) 19 (55.9%) 15 (50.0%)
Caucasian–American 30 (46.9%) 15 (44.1%) 15 (50.0%)
Gender
Male 41 (64.1%) 26 (76.5%) 15 (36.6%)
Female 23 (35.9%) 8 (34.8%) 15 (65.2%)
Genotype
1a 34 (53.1%) 19 (55.9%) 15 (50.0%)
1b 24 (37.5%) 15 (44.1%) 0 (0%) 9 (5.3%)
Other 6 (9.4%) 6 (0.2%)
13 3
1a/b 2 2
Indeterminate 1 1
Viral level, IU/ml (log10)
Mean (SD) 6.3 (0.7) 6.4 (0.7) 6.1 (0.6)
Median (25th, 75th) 6.4 (5.7, 6.8) 6.5 (6.2, 6.9) 6.2 (5.6, 6.5)
Alanine aminotransferase (IU/l)
Mean (SD) 84.8 (77.3) 83.2 (57.2) 86.6 (96.3)
Median (25th, 75th) 60.0 (41.5, 99.5) 65.5 (50.0, 105.0) 53.0 (38.0, 98.0)
Total HAI inflammation
Mean (SD) 8.6 (2.9) 8.8 (2.8) 8.3 (3.1)
Median (25th, 75th) 8.0 (6.5, 11.0) 8.0 (7.0,11.0) 8.0 (6.0, 11.0)
Ishak fibrosis score
0 12 (18.8%) 4 (11.8%) 8 (26.7%)
1, 2 29 (45.3%) 15 (44.1%) 14 (46.7%)
3, 4 21 (32.8%) 13 (38.2%) 8 (26.7%)
5, 6 2 (3.1%) 2 (5.9%) 0 (0.0%)
HOMA
(2 30 (46.9%) 13 (38.2%) 17 (56.7%)
.2 25 (39.1%) 15 (44.1%) 10 (33.3%)
Missing 9 (14.1%) 6 (17.7%) 3 (10.0%)
28 day response
Poor 37 (57.8%) 26 (76.5%) 11 (29.7%)
Intermediate 10 (15.6%) 3 (8.8%) 7 (23.3%)
Marked 16 (25.0%) 4 (11.8%) 12 (40.0%)
Rebound .1.4 1 (1.6%) 1 (2.9%) 0 (0.0%)
Early virological response (week 12 response)
Non-responder 19 (29.7%) 18 (52.9%) 1 (3.33%)
Responder 45 (70.3%) 16 (47.1%) 29 (96.7%)
At 28 days poor response was defined as ,/=1 log decrease, intermediate 1–3.5 log decrease, marked .3.5 log decrease in
viral level. Early virological response was defined as RNA negativity at 12 weeks of therapy. Sustained virological response was
defined as RNA negativity at 24 weeks after cessation of therapy.
HAI, histological activity index; HOMA, homeostasis model assessement.
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therapy. In contrast to prior studies of DC maturation in HCV
which used cultured-derived DCs, we studied patient samples
analysed directly ex vivo from the large Virahep-C treatment
trial. We examined chemokine receptors, maturation markers,
and co-stimulatory markers on DC subsets, as well as the ability
of pDCs and mDCs to migrate to chemokines relative to
histological injury and treatment outcome. For the first time,
we demonstrate incomplete maturation of the pDC subtype in
hepatitis C, which resolves with successful therapy. We also
show that therapeutic non-responders have increased pDC
migration to inflammatory chemokines before therapy when
compared with therapeutic responders.
METHODS
Study population
Virahep-C is a multicentre collaborative observational study
primarily designed to examine racial differences (Caucasian vs
African–American) in naı ¨ve HCV genotype 1 treatment
response rates to combination therapy (pegylated IFNa-2a and
ribavirin). The methods and overall demographics of the 401
patients in the Virahep-C study have been described pre-
viously.
37 Patients received 48 weeks of combination therapy
unless they were HCV RNA positive at week 24; in these
patients, therapy was stopped. We randomly selected a cohort
of 64 patients with adequate cell numbers from the Virahep-C
group based on matching equal numbers of patients in four
groups by sustained virological response (SVR defined as HCV
RNA negative 24 weeks after the end of therapy) and race
(Caucasian vs African–American). Extensive demographic data
was available on all patients and the characteristics of the study
cohort are shown in table 1. The data in our cohort did not
differ significantly from the full cohort of 401 patients.
37 All
patients were genotype-1, the mean age was 48 years; 64% were
male and 53% were African–American (AA). Ninety seven per
cent of patients had an Ishak score 4/6 or lower and the mean
histological activity index (HAI) score was 8.6/18. Seventy per
cent of patients had an early virological response (greater than 2
log decrease in HCV RNA after 12 weeks of therapy). Thirty
patients achieved SVR while 34 did not. SVR positive patients
were more likely to be female, have lower levels of insulin
resistance (homeostasis model assessment (HOMA)), and have
an early virological response (EVR) and rapid virological
response (RVR) as described previously and shown in table 1.
37
PBMCs from 20 healthy volunteer patients served as normal
controls. The average age of controls was 37; 63% were male,
and 50% were AA.
PBMCs were isolated from whole blood by Ficoll (Amersham,
Piscataway, New Jersey, USA) density gradient centrifugation
or cellular preparation tubes (Becton-Dickinson, San Jose,
California, USA). PBMCs were viably frozen in 80% fetal
bovine serum (BioWhittaker, Basel, Switzerland), 10% dimethyl
sulfoxide (DMSO), and 10% RPMI 1640 media (Life
Technologies, Carlsbad, California, USA) in liquid nitrogen for
subsequent analyses.
Flow cytometry
PBMCs were thawed into RPMI with 10% human serum, and
two million PBMCs per tube were stained with the following
antibodies according to the manufacturer’s recommendations.
Figure 1 Representative gating strategy
for isolation of dendritic cell (DC)
subtypes. Two million PBMCs were
stained with BDCA-1-APC and BDCA-2-
FITC. Additionally, peridinin chlorophyll
protein (PerCP) and R-phycoerythrin (PE)-
labelled antibodies were used to measure
surface marker expression by 4-color flow
cytometry. Forward scatter and side
scatter identified and gated live cells in
region 1 (R1) (A,B). Side scatter and
either BDCA-2 (A, pDC) or BDCA-1 (B,
mDC) were used to identify and gate DC
subtypes in region 2 (R2).
39 40 Overlay
plots comparing isotype antibody controls
with specific marker staining were used.
The thicker line is the isotype control, the
thinner line shaded with grey is staining
with antibody to the protein indicated
below the graph. The gate used is the
horizontal bar labelled M1. (A) pDC gating
and representative expression.
APC, allophycocyanin; FITC, fluorescein
isothiocyanate; mDCs, myeloid dendritic
cells; pDCs, plamscytoid dendritic cells;
PMBCs, peripheral blood mononuclear
cells. (Figure 1B is on p 967.)
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(Bergisch Gladbach, Germany). CXCR3, CXCR4, CCR5,
CCR7, CD83, CD86, DC-sign were from BD biosciences
(Becton Dickinson). CD40 was from Ancell (Bayport,
Minnesota, USA). Appropriate isotype control antibodies were
utilised. After incubation with antibodies for 20 min in the dark
at 4uC, cells were washed once with cold phosphate-buffered
saline (PBS) containing 0.6% bovine serum albumin and 0.01%
sodium azide and fixed in 2.5% paraformaldehyde. Acquisition
and analysis was performed using a Becton-Dickinson
FACSCalibur flow cytometer running CellQuest Pro software
at the University of Colorado Denver Clinimmune flow
cytometry core facility. Because BDCA-1 is expressed on a
subset of CD19
+ B-cells, we tested for CD19
+ cells in the BDCA-
1 gate. We found gating on high BDCA-1 expression reduced
CD19
+ cells to less than 5% of the mDC gate (data not shown).
Some patients did not have enough PBMCs saved to analyse
every marker therefore small variations occurred in patient
numbers per experiment.
Chemotaxis
Twenty patients from the original cohort of 64 patients were
chosen for study based on the availability of sufficient numbers
of cells for analysis. Seven normal patients from the group
mentioned above were used as controls. CXCL12 and CXCL10
chemokines were purchased from Preprotech. Two million
PBMCs in RPMI in 10% human serum were added to the upper
well of a 6.5 mm, 5 mm pore transwell chamber (Corning,
Pittsburgh, Philadelphia, USA).
38 The bottom chamber con-
tained the same media plus chemokine. After a 3 h incubation,
cells in the bottom chamber were collected using ice cold PBS
containing 10 mmol/l EDTA. The collected cells were stained
with BDCA-1–APC and BDCA-2–FITC and counted in a BD
Canto flow cytometer. Fifty thousand unlabelled beads (Bang
Laboratories, Fishers, Indiana, USA) were added to each sample
and used as a control for counting efficiency. We performed each
analysis in duplicate. We calculated and plotted the chemotaxis
index, defined as the ratio of cells migrated with chemokine
divided by the number of cells migrated without chemokine.
Statistical analysis
Descriptive statistics, including medians, means, standard
deviations and frequencies are tabulated for the raw counts
separately for the patient groups. The two-tailed non-para-
metric Wilcoxon signed rank-sum test was used to compare
paired DC measurements before and after therapy. Correlation
between chemotaxis and histological activity index were
assessed using the Spearman rank correlation coefficient. In
order to examine the association between baseline DC
measurements and SVR, weighted generalised estimating
equations (GEEs) modelling approach (proc genmod in SAS)
was utilised. Comparisons in DC measurements between the
HCV cohort and normal controls were done by permutation
test using a sum of ranks as a statistic since we have relatively
unbalanced sample sizes between the two groups. A p value of
less than 0.05 was considered significant and not adjusted for
multiple testing. Permutation tests were done in R package
version 2.7 (available at http://CRAN.R-project.org/). Other
statistical analyses were performed using JMP 6.0, SAS 9.1.3 and
Prism 5.01 (GraphPad Software, San Diego California USA).
Figure 1 Continued. Representative
gating strategy for isolation of DC
subtypes. Two million PBMCs were
stained with BDCA-1–APC and BDCA-2–
FITC. Additionally, PerCP and PE labelled
antibodies were used to measure surface
marker expression by four-colour flow
cytometry. Forward scatter and side
scatter identified and gated live cells in
region 1 (R1) panels (A,B). Side scatter
and either BDCA-2 (A, pDC) or BDCA-1
(B, mDC) were used to identify and gate
DC subtypes in region 2 (R2).
39 40 Overlay
plots comparing isotype antibody controls
with specific marker staining were used.
The thicker line is the isotype control, the
thinner line shaded with grey is staining
with antibody to the protein indicated
below the graph. The gate used is the
horizontal bar labelled M1. (B) mDC
gating and representative expression.
Median fluorescence intensity in the
gated region M1 was calculated by
CellQuest Pro software and used in
subsequent analysis.
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Flow cytometry
We analysed PBMCs that were isolated 2 weeks before
initiation (screening 2 weeks, ‘‘S002’’) and 24 weeks after
cessation of therapy (follow-up week 24, ‘‘FU24’’) by flow
cytometry. Figure 1 demonstrates the gating strategy utilised to
separate and analyse plasmacytoid dendritic cells (pDCs) and
myeloid dendritic cells (mDCs). As previously described by
other groups, mDCs were defined as BDCA-1 positive and pDCs
were defined as BDCA-2 positive.
30 39–43
Figure 2 Comparison of plasmacytoid
dendritic cells (pDCs) and myeloid
dendritic cells (mDCs) between normal
controls and hepatitis C virus (HCV)
patients 2 weeks before starting therapy.
SOO2 is the visit 2 weeks before initiation
of therapy. FU24 is 24 weeks after
cessation of treatment. Median
fluorescence intensity (MFI) values for
each patient are shown. The horizontal
line is the median. A two-tailed Mann–
Whitney test was used to calculate p
values. (A) Per cent of cells in region R1
is shown, CXCR3 MFI, CXCR4 MFI and
CCR5 MFI. (B) CD83, CD86, CD40, HLA-
DR MFI.
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chronic HCV
Consistent with prior studies,
18 19 44 45 we found the percentage of
pDCs in chronic HCV patients (median 0.32%, range 0.08–1.44%)
was slightly reduced compared with normal patients (0.39%,
0.17–5.1% p=0.0323) (fig 2). Chronic HCV patients had slightly
lower levels of mDCs (median 0.53%, range 0.16–2.08%)
compared with normal patients (0.73%, 0.33–1.56%, p=0.0245)
(fig 2). In SVR+ patients (fig 3A), the per cent of pDCs increased
significantly towards normal controls after therapy (median
0.31–0.36%, p=0.0497), while in the SVR2 patients, they did
not (0.33–0.30%). In contrast, mDCs did not change significantly
in either group (fig 3A). No significant pre-treatment differences
in per cent pDCs or mDCs was noted comparing SVR+ and
SVR2 patients.
Inflammatory chemokine receptors increased on plasmacytoid
dendritic cells in HCV patients
We measured levels of DC chemokine receptors before and after
therapy, focusing on the inflammation-homing receptors
CXCR4, CXCR3, CCR5 and CCR7, the latter being important
for mature DCs to migrate to lymphoid organs to present
antigen.
30 33 34 36 Plasmacytoid DC MFI levels of CXCR4 (median
181, range 79–542) and CXCR3 (median 362, range 28–1582)
were significantly elevated before therapy compared with
normal controls (median 102, range 34–219, p=0.0002, median
90, range 28–820, p,0.0001, respectively) (fig 2A). Combination
therapy significantly decreased pDC CXCR4 expression toward
normal levels with a larger decrease seen in patients with SVR
compared with non-SVR patients (median 193 to 115 compared
with median 177 to 160, fig 3A). CXCR3 levels on pDCs also
Figure 3 Differential elevations of
chemokine receptors and maturation
markers in dendritic cell (DC) subtypes
before and after therapy. SOO2 is
screening visit 2, 2 weeks before
initiation of therapy. FU24 is 24 weeks
after cessation of treatment. Median
fluorescence intensity (MFI) values for
each patient are shown. The horizontal
line is the median. A two-tailed non-
parametric Wilcoxon signed rank test
was used for paired data or the two-tailed
Mann–Whitney test was used to
calculate p values. (A) Per cent DCs;
CXCR4 MFI for pDCs and mDCs; CXCR3
MFI for pDCs and mDCs. mDCs, myeloid
dendritic cells; pDCs, plasmacytoid
dendritic cells. (Figure 3 continues on
p 970.)
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and SVR2 (p=0.0018) patients (fig 3A). In mDCs, CXCR4
baseline levels were not elevated compared with normal
controls and a decrease in expression levels occurred in SVR+
patients only (p=0.0004) (figs 2A, 3A). Levels of CXCR3 on
mDCs were decreased compared with normal controls and
decreased with successful therapy only (figs 2A, 3A). CCR5
expression levels were not significantly different on pDCs and
mDCs between normal subjects (fig 2A). CCR7 expression was
either extremely low or undetectable on pDCs and mDCs
(fig 1A,B) consistent with prior reports of low peripheral
expression levels in unstimulated pDCs.
25 46 47
HCV plasmacytoid dendritic cells have a partially activated
phenotype
We also measured levels of the co-stimulatory molecules CD40
and CD86, MHC class II (HLA-DR), the maturation marker
CD83, and the viral binding protein DC-SIGN. We observed
that pre-treatment pDCs from patients had elevated levels of
CD40 (median 234, range 102–2641) and CD83 (median 514,
range 26–1860) compared with normal controls (147, 66–294,
p=0.0001; 50, 15–1065, p=0.0002) (fig 2B). A significant
decrease in CD40 and CD83 towards normal values occurred
only in SVR+ patients (p=0.0365, p=0.0068, respectively,
fig 3B) compared with SVR2 patients whose levels remained
elevated. Pre-treatment HLA-DR levels (median 275, range
79–635) were significantly lower on pDCs compared with
normal controls (median 375, range 115–679) while mDCs were
not significantly different (fig 2). SVR2 patients had a small but
statistically significant decrease in mDC HLA-DR MFI
(p=0.0102) after therapy while SVR+ patients did not
(fig 3B). CD86 levels on mDCs were decreased compared with
normal patients and no significant change in MFI occurred after
therapy. CD86 expression was generally low to absent on pDCs
from all groups (no increase above isotype control, fig 1A).
CD83 mDC levels were not significantly different from controls
Figure 3 Continued. Differential
elevations of chemokine receptors and
maturation markers in dendritic cell (DC)
subtypes before and after therapy. SOO2
is screening visit 2, 2 weeks before
initiation of therapy. FU24 is 24 weeks
after cessation of treatment. Median
fluorescence intensity (MFI) values for
each patient are shown. The horizontal
line is the median. A two-tailed non-
parametric Wilcoxon signed rank test
was used for paired data or the two-tailed
Mann–Whitney test was used to
calculate p values. (B) CD83 MFI on
pDCs, mDCs; CD40 MFI for pDCs, mDCs;
HLA-DR for pDCs and mDCs.
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SIGN was not detected on pDCs and mDCs in PBMC from all
groups (data not shown).
No association between pre-treatment expression levels of
dendritic cell markers and sustained virological response
The associations between pre-treatment DC measurements
described above and SVR were examined by weighted GEE-type
regression analysis adjusted for race. In addition, we also
examined a possible confounding effect of other clinical and
laboratory characteristics of the cohort by including a subject’s
gender, age, baseline histology using HAI scores, baseline viral
levels, ALT level, and measurement of insulin resistance
(HOMA) one at a time in each regression model. Overall, we
did not observe significant association between DC markers and
chemokines and SVR whether the model was adjusted or
unadjusted for clinical and laboratory characteristics (data not
shown).
Baseline chemotaxis is higher in patients with sustained viral
release: correlation of dendritic cell chemotaxis to hepatic
inflammation
Since chemotaxis has such an important role in DC function,
we next examined whether differences in chemokine surface
receptor expression led to functional differences in DC
chemotaxis. Because CXCR4 and CXCR3 chemokine receptors
levels were elevated on pDC, and these levels decreased more in
patients who had SVR, we decided to analyse the ability of DCs
to migrate towards chemokines SDF-1 (CXCL12) and IP-10
(CXCL10), which signal through CXCR4 and CXCR3, respec-
tively.
32 We selected 20 patients (10 SVR+, 10 SVR2) with
sufficient PBMCs for analysis from the original cohort of
patients before and after HCV therapy. Overall, there was
greater pDC and mDC migration towards CXCL12 than
CXCL10 in both normal patients and chronic patients before
therapy (fig 4). Combining all patients at timepoint S002, the
mean chemotaxis index of pDC to CXCL12 was 4.708 versus
1.007 for CXCL10 (p,0.0001). Mean migration for mDCs was
6.533 to CXCL12 vs 1.255 to CXCL10 (p,0.0001).
Pre-treatment migration of pDCs to CXCL12 was higher in
SVR2 patients (median 6.0, range 1.3–12) compared to SVR+
patients (median 3.8, range 1.4–5.4) (p=0.0185, fig 4). Pre-
treatment migration of pDCs to CXCL10 was also slightly
higher in SVR2 patients (median 1.29, range 0.69–1.7) vs (0.78
0.56–1.06, p=0.0106, fig 4). Chemotaxis decreased after
therapy but this change was not statistically significant.
Myeloid DCs from SVR+ and SVR2 patients showed no
significant differences in their responses to CXCL12 or CXCL10
but the trends in migration were similar to pDCs (data not
shown). Increasing pDC migration to CXCL12 correlated
significantly with pre-treatment total HAI score (18 maximum
points)
37 48 and periportal+portal inflammation subscores (8
maximum points) (p=0.0329, p=0.0234, respectively; fig 5),
but not lobular inflammation. There was no association
between chemotaxis and viral level (data not shown).
Migration of pDCs to CXCL10 directly correlated with
periportal+portal inflammation (p=0.0399) but only
approached statistical significance for total HAI score
(p=0.0640; fig 5). In contrast, mDC migrations to CXCL12
and CXCL10 were not significantly associated with inflamma-
tion (data not shown).
DISCUSSION
HCV may inhibit the immune response of DCs, hindering the
adaptive response from T cells.
13 47 We hypothesised that DC
dysfunction may determine the response to PEG-IFN/ribavirin
therapy. In this large HCV treatment study of 64 patients, using
ex vivo analysis, we found that pDCs and mDCs were decreased
compared to normal controls, consistent with prior studies in
HCV and similar to prior studies of patients with
HIV.
13 18 19 38 44 45 49 For the first time, we found that pDCs from
HCV patients had elevated levels of the inflammatory
chemokine receptors CXCR4 and CXCR3 before therapy, and,
importantly, successful therapy was associated with larger
decreases in expression levels. High chemokine and inflamma-
tory cytokine levels in the blood of HCV patients likely
increases chemokine receptor expression.
32 The co-stimulatory
molecule CD40 and the maturation marker CD83 were elevated
on pDCs and decreased with SVR. Lower pre-treatment HLA-
DR was seen on pDCs in HCV patients compared to normal
controls. The maturation marker DC-SIGN, and the co-
stimulatory molecule CD86 were not elevated, suggesting that
Figure 4 Increased baseline plamacytoid dendritic cell (pDC)
chemotaxis to CXCL12, CXCL10 in SVR2 patients. Ten SVR+ and 10
SVR2 patients from the original cohort of 64 patients were compared
with seven normal controls. Chemotaxis index (CI) was defined as the
number of cells migrated with chemokine divided by the number of cells
that migrated without chemokine. CXCL12 was used at 200 ng/ml,
CXCL10 at 1 mg/ml. The Mann–Whitney test or the Wilcoxon signed
rank test (for paired samples) was used to calculate p values. The
horizontal line is the median. (A) Chemotaxis of pDCs to CXCL12. (B)
Chemotaxis of pDCs to CXCL10 (note: 9/10 patients studied in the SVR2
group had sufficient PBMCs for study).
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baseline DC marker phenotype did not predict SVR, including
data analysis by race comparing Caucasians versus African–
Americans.
For mDCs, there were fewer differences in marker expression
between HCV and normal patients and the differences in
expression level were small, suggesting that HCV infection
affects pDCs in the peripheral blood more than mDCs.
Supporting our findings, a recent paper demonstrated that
infectious cell culture-derived HCV inhibited pDC IFNa
production whereas mDCs were not affected.
47
Fully activated DCs express the chemokine receptor CCR7
which is important for lymph node homing, HL-DR for antigen
presentation, co-stimulatory and maturation markers like
CD40, CD86 and CD83.
14 Partial or incomplete activation seen
in our study has also been described in DCs from other chronic
viral infections, such as HIV.
38 A recent study of HIV patients
showed elevated CD40 on mDCs and pDCs with low CD86,
with even higher levels of CD40 seen in lymph nodes.
38 In
chronic HCV, this phenotype may result from chronic infection
and inflammation in the liver and peripheral blood that is not
sufficiently robust enough to cause full activation. These
partially activated pDCs may be poor presenters of antigen
because of low MHC surface levels and poor activators of T cells
because they have low levels of co-stimulatory molecules.
However, we recognise a limitation of our study was that we
sampled DCs from the peripheral blood, a compartment where
they are transiently; thus, we might be observing partial
activation occurring secondary to inflammatory cytokine
stimulation before DC migration to areas of inflammation.
We chose to study chemotaxis of DCs after observing
differences in chemokine receptor levels between treatment
response groups and because a prior study
30 suggested that
chemotaxis may be altered in HCV infection. Natterman et al
described increased pDCs and mDCs in the livers of chronic
HCV patients that may explain the decrease of DC seen in the
periphery.
30 Additionally, sera from HCV patients, and the HCV
protein E2 inhibited in vitro migration to CCL21, a CCR7-
binding chemokine important for lymph node homing.
Natterman et al hypothesised that DCs are trapped in the liver
and are unable to activate T cells in lymph nodes. We feel that
our data are consistent with their hypothesis. We found that
baseline chemotaxis to the inflammatory chemokines CXCL12
and CXCL10 was elevated in all patient groups compared with
normal controls, consistent with our chemokine receptor
expression data. Additionally, SVR2 patients demonstrated
increased pre-treatment chemotaxis to CXCL12 and CXCL10
compared to SVR+ patients. Hepatic inflammation levels
showed significant correlation with chemotaxis in the patients
studied. These observations are in accord with prior studies
demonstrating that higher plasma pre-treatment levels of
CXCL10 and CXCL8 were associated with an unfavourable
response to combination therapy.
33–35 A limitation of our study
was that we were unable to study intrahepatic DCs from our
patients to determine whether DC egress to the lymph node is
compromised as proposed by Natterman et al.
30
Why is increased baseline inflammation associated with a
poorer response to therapy? Recent studies of gene expression in
liver biopsy samples and PBMCs have demonstrated that
patients with higher levels of interferon-stimulated genes before
therapy have a poorer response to interferon/ribavirin.
50–52 These
results suggest that non-responding patients already have
maximal interferon responses and that adding additional
interferon does not augment the antiviral immune response.
In summary, pDCs from patients with chronic HCV analysed
directly ex vivo show increased inflammatory chemokine
receptor expression and a partial activation phenotype that
suggests pDC dysfunction. Successful antiviral therapy nor-
malises many phenotypic and functional abnormalities of
pDCs from patients with HCV. Our finding that pDCs in
Figure 5 Increased plasmacytoid
dendritic cell (pDC) chemotaxis to
CXCL12, CXCL10 correlates with
inflammation. Combining all 20 patients
together, chemotaxis index at S002 (pre-
treatment) was plotted against the total
histological activity index (HAI)
37 48 (total
0–18) which includes a sub-score for
periportal inflammation, portal
inflammation, and fibrosis from the
patients’ liver biopsy. The p value and
correlation coefficient R for the
association between the variables is
shown. Analysis performed by GraphPad
Prism software using the two-tailed
Spearman’s test. (A) CXCL12 pDC total
HAI score, CXCL12 periportal+portal HAI
score. (B) CXCL10 pDC total HAI score,
CXCL10 pDC periportal+portal HAI score.
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972 Gut 2009;58:964–973. doi:10.1136/gut.2008.168948SVR2 patients demonstrate increased chemotaxis before therapy
reinforces the hypothesis that increased baseline inflammation is
associated with failure to respond to antiviral therapy. It remains
tobedeterminedifDCmigrationfromlivertolymphnodeand/or
antigen presentation to T cells is inhibited in vivo. Further
functional studies of HCV DCs may lead to improved immune-
boosting therapies for viral eradication.
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